XTL Biopharmaceuticals Ltd (XTLB) ADR Each Repr 100 Shs Spon

Sell:$1.12Buy:$1.39$0.03 (2.13%)

Prices delayed by at least 15 minutes
Sell:$1.12
Buy:$1.39
Change:$0.03 (2.13%)
Prices delayed by at least 15 minutes
Sell:$1.12
Buy:$1.39
Change:$0.03 (2.13%)
Prices delayed by at least 15 minutes

Company Information

About this company

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Key people

Noam Band
Chief Executive Officer
Itay Weinstein
Chief Financial Officer
Shlomo Shalev
Chairman of the Board
Dobroslav Melamed
Non-Executive Director
Alexander Rabinovitch
Non-Executive Director
Jonathan Schapiro
Non-Executive Director
Doron Turgeman
Non-Executive Director
Click to see more

Key facts

  • EPIC
    XTLB
  • Location
    Israel
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US98386D3070
  • Market cap
    $10.74m
  • Employees
    0
  • Shares in issue
    514.21m
  • Exchange
    Tel Aviv Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.